Oncotarget

Meta-Analysis:

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

Min Yu _, Han Yongzhi, Shengying Chen, Xiaodan Luo, Ye Lin, Yu Zhou, Haosheng Jin, Baohua Hou, Yanying Deng, Lei Tu and Zhixiang Jian

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:43356-43367. https://doi.org/10.18632/oncotarget.17445

Metrics: PDF 2373 views  |   HTML 3428 views  |   ?  


Abstract

Min Yu1,*, Han Yongzhi2,*, Shengying Chen1,*, Xiaodan Luo3, Ye Lin1, Yu Zhou1, Haosheng Jin1, Baohua Hou1, Yanying Deng1, Lei Tu1 and Zhixiang Jian1

1Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

2Department of Dermatology, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, China

3Department of Infectious Diseases, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, China

*These authors contributed equally to this work

Correspondence to:

Min Yu, email: yuminzhongda@163.com

Keywords: glucose transporter 1, prognostic marker, survival, cancer, glycolysis

Received: July 18, 2016     Accepted: April 06, 2017     Published: April 27, 2017

ABSTRACT

Increased glycolysis is one of the hallmarks of cancer. The abnormal expression of glucose transporter 1 (GLUT1) was reported to be associated with resistance to current therapy and poor prognosis. Numerous studies have investigated the correlation between GLUT1 expression and prognosis in cancers, but the conclusions are still controversial. Here, we conducted a meta-analysis to explore the association between GLUT1 and survival in human cancers. PubMed, Springer, Medline, and Cochrane Library were searched carefully to identify eligible studies evaluating prognostic value of GLUT1 in cancers. Twenty-seven studies with 4079 patients were included in the present study. Our pooled results identified that increased expression of GLUT1 was associated with unfavorable overall survival (HR = 1.780, 95% CI = 1.574–.013, p < 0.001)) and poorer disease-free survival (HR = 1.95, 95% CI = 1.229–3.095, p = 0.003). Furthermore, overexpression of GLUT1 linked with poor differentiated tumors (RR = 1.380, 95% CI = 1.086–1.755, p = 0.009; I2 = 72.0%, p < 0.001), positive lymph node metastasis (RR = 1.395, 95% CI = 1.082–1.799, p = 0.010; I2 = 70.8%, p = 0.002) and larger tumor size (RR = 1.405, 95% CI = 1.231–1.603, p < 0.001; I2 = 37.3%, p = 0.093). This systematic review and meta-analysis indicated that the GLUT1 may serve as an ideal prognostic biomarker in various cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17445